Every week, RealBio® Technology hosts an interactive, web-based session to explain how this technology can benefit your research and improve your results. Attendees automatically receive an in-depth overview of the RealBio D4 ™ Culture System in advance of the session.

YES! I'd like to attend an upcoming webinar to learn more.
Name:
Organization:
Phone:
Email:
RealBio® Technology continually strives to provide the latest information on advancements in the life sciences research field. Please add me to the RealBio® Technology periodic e-mail update list so I can stay informed on these advances. Privacy Policy



Scientific Advisory Board

Edward LeCluyse, Ph.D.

Senior Research Investigator in the Institute for Chemical Safety Sciences at The Hamner Institutes for Health Sciences, and is an Adjunct Associate Professor in the Curriculum in Toxicology at The University of North Carolina at Chapel Hill (UNC).


Dr. Dalia Cohen M.Sc., Ph.D.

Founder and President, ALN Associates

Dr. Cohen is a pharmaceutical industry expert in the intersection of drug discovery, personalized medicine and genomic technologies with over 25 years of experience. Most recently, Dr. Cohen served as the Chief Scientific Officer at Asterand. Before this appointment, Dr. Cohen served as the Chief Scientific Officer of Rosetta Genomics, a microRNA-based diagnostic company. During her four years at Rosetta Genomics, she led the company's product development and launched three cancer diagnostic tests.

Prior to joining Rosetta Genomics, Dr. Cohen worked for 15 years at Novartis and held several executive positions including Vice President & Global Head of the Functional Genomics Department where she led multi-disciplinary teams in Switzerland and the United States.


J. Patrick McGovren, Ph.D.

Dr. McGovren has a Ph.D. in Pharmaceutical Sciences and extensive pharmaceutical industry and start-up experience in the preclinical and clinical development of anticancer drugs. He was deeply involved in the discovery and/or development of 10 clinically evaluated antitumor drugs. Pat was a key advocate for The Upjohn Company's successful in-licensing of irinotecan which was marketed as Camptosarâ„¢ Injection and became a significant colorectal cancer product with $500 MM per annum US sales. During his laboratory career, Dr. McGovren was responsible for screening and detailed evaluation of test compounds in mouse tumor models as well as the preclinical pharmacology and pharmacokinetics of lead compounds. Later he worked as a clinical operations manager for phase IV/post-marketing studies, and then moved into Pharmacia's clinical pharmacology group. He has prepared IND and NDA preclinical and clinical pharmacology sections and participated in resolving numerous clinical pharmacology-related regulatory issues.


James McKim, Ph.D.

Dr. McKim is Chief Scientific Officer and Founder of Ceetox, Inc., a contract research organization focused on in vitro toxicity screening of potential drug candidates and chemicals. Formerly, he was director of Pfizer's Global Center of Excellence for In Vitro Toxicology where he developed and patented algorithms assessing in vivo toxicity using in vitro data. Dr. McKim is leveraging the benefits of the RealBio D4™ Culture System to assist Ceetox researchers in providing enhanced performance and improved results for their clients.

Board of Advisors

George Dunbar

George Dunbar joined Arboretum Ventures in 2010 as a Venture Partner. George utilizes his extensive healthcare operating experience as the former CEO of a number of public and private venture-backed healthcare companies to evaluate new investment opportunities in the diagnostics, life sciences tools and medical devices sectors. George currently serves as the Chairman of Arboretum portfolio company Accuri Cytometers and Director with CerviLenz and Life Magnetics.

Prior to joining Arboretum Ventures, George was most recently the President, CEO and Chairman of Aastrom Biosciences, a publicly-traded, clinical development stage healthcare company based in Ann Arbor. Prior to Aastrom, Mr. Dunbar worked with several national venture capital firms, serving as the CEO of a number of early-stage life sciences companies, including Quantum Dot (acquired by Invitrogen) and Epic Therapeutics (acquired by Baxter Healthcare). He has also held senior positions in licensing, business development and marketing with The Ares-Serono Group and Amersham International, now GE Healthcare.

George is a graduate of Auburn University, holding both a Master's degree in Business Administration and an undergraduate degree in Electrical Engineering, and currently sits on the MBA Advisory Board of the College of Business at Auburn.


Jerry Culp

Jerry Culp has a 25 year history of leading the conceptualization, development and commercialization of many high tech product platforms. For the past 19 years Jerry has been with the Stryker Corporation and currently serves as Vice President, Global Development where he is responsible for team and technology architectures required to ensure Stryker's leadership in future medical markets. Previously Jerry served as Vice President, Research and Development at Stryker's Instruments Division where he delivered numerous commercially successful product platforms to the market. Before his tenure at Stryker, Jerry was with Radian Research where he served as Director, Research and Development. Radian Research is a world leader in providing metrology level calibration equipment to the electric utility industry. Jerry is an electrical engineer by training and has a BS from Purdue University.


Lee Noll

Lee is the co-founder and past CEO/President/Chairman of BioFlow Technology, Inc., a life science company developing and marketing 3D culture system tools. Previously Lee held positions at Corning Inc., Charles River, New View VIP, and Aastrom Biosciences, Inc., and has extensive experience in management, quality assurance, and technical services. Lee holds a Bachelor of Science from Michigan State University.